Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Exact Sciences Corporation - Common Stock (NQ:EXAS)

56.42 +0.25 (+0.45%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Exact Sciences Corporation - Common Stock

< Previous 1 2 3 Next >
Exact Sciences Earns 2025 Great Place To Work® Certification™
From Exact Sciences Corp.
Via Business Wire
Exact Sciences to Participate in May Investor Conference
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Announces First-Quarter 2025 Results
From Exact Sciences Corp.
Via Business Wire
Exact Sciences to Highlight Cologuard® Test Adherence and Predicted Preference Data at Digestive Disease Week (DDW) 2025
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Launches the Oncodetect™ Molecular Residual Disease Test
From Exact Sciences Corp.
Via Business Wire
JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Schedules First Quarter 2025 Earnings Call
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Named 2025 Gallup Exceptional Workplace Award Winner
From Exact Sciences Corp.
Via Business Wire
Exact Sciences to Participate in March Investor Conferences
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Announces Fourth Quarter 2024 Results
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Schedules Fourth Quarter 2024 Earnings Call
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Demonstrates Leadership in Cancer Innovation with New Data on Screening and Molecular Residual Disease at 2025 ASCO GI Symposium
From Exact Sciences Corp.
Via Business Wire
New Evidence Validates Oncodetect's™ Ability to Detect Molecular Residual Disease and Predict Recurrence in Colorectal Cancer Patients
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Announces Preliminary Fourth Quarter 2024 Results
From Exact Sciences Corp.
Via Business Wire
Exact Sciences to Participate in J.P. Morgan Healthcare Conference
From Exact Sciences Corp.
Via Business Wire
Exact Sciences to Participate in December Investor Conferences
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Announces Third-Quarter 2024 Results
From Exact Sciences Corp.
Via Business Wire
Exact Sciences to Participate in November Investor Conference
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Presents Multiple Studies at ACG 2024 Demonstrating Leadership in Noninvasive Colorectal Cancer Screening and Patient Engagement
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Schedules Third Quarter 2024 Earnings Call
From Exact Sciences Corp.
Via Business Wire
FDA Approves Exact Sciences’ Cologuard Plus Test, Setting a New Benchmark in Non-Invasive Colorectal Cancer Screening
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024
From Exact Sciences Corp.
Via Business Wire
Exact Sciences to Participate in September Investor Conferences
From Exact Sciences Corp.
Via Business Wire
Sector Spotlight: Top 4 Basket of Diagnostic Stocks (EXAS, GH, ILMN, LUDG)
Via AB Newswire
Exposures COVID-19
Exact Sciences Announces First Patient Enrolled in its Multi-Cancer Early Detection (MCED) Falcon Registry Real-World Evidence Study
From Exact Sciences Corp.
Via Business Wire
New Modeling Data Show the Cologuard® Test Has Detected More Than 623,000 Cancers and Precancers Over Past Decade, Saving U.S. Health Care System $22 Billion
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Announces Second-Quarter 2024 Results
From Exact Sciences Corp.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.